CAR-T赛道的下一个破局者

药智网
22 Mar

在资本市场对创新药企的估值逻辑从“管线故事”转向“商业化答卷”的当下,这家手握14.79亿元现金储备的创新药企,如何持续书写在CAR-T赛道的创新故事?01首个产品上市2024年2月,科济药业迎来历史性时刻——全球首款固定剂量全人源抗BCMA CAR-T疗法赛恺泽®正式获批上市,用于治疗复发或难治性多发性骨髓瘤成人患者,既往经过至少3线治疗后进展(至少使用过一种蛋白酶体抑制剂及免疫调节剂)。作为...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10